Want to see BEAM full AI Analyst Report?
BEAM Stock Chart & Stats
$25.10
-$0.81(-3.13%)
At close: 4:00 PM EDT
$25.10
-$0.81(-3.13%)
Day’s Range― - ―
52-Week Range$15.60 - $38.26
Previous CloseN/A
Volume1.81M
Average Volume (3M)2.52M
Market Cap
$2.58B
Enterprise Value$1.50K
Total Cash (Recent Filing)$1.21B
Total Debt (Recent Filing)$250.82M
Price to Earnings (P/E)―
Beta2.32
Next Earnings
Aug 11, 2026EPS Estimate
-1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding102,879,210
10 Day Avg. Volume2,330,625
30 Day Avg. Volume2,517,261
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)2.21
Price to Sales (P/S)19.62
P/FCF Ratio-7.61
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$52.91Price Target Upside110.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-4.37
Revenue Forecast (FY)$82.09M
Bulls Say, Bears Say
Bulls Say
Balance Sheet HealthModest leverage and a sizable equity base provide a durable financial buffer for an R&D-intensive biotech. Low debt reduces near-term refinancing risk and increases flexibility to fund clinical programs, partnerships, or opportunistic M&A without immediate solvency pressure.
Revenue Growth TrendSustained top-line growth shows improving commercial traction of the platform and validates collaborator funding. Growing revenue, even if partnership-driven, helps lengthen runway and demonstrates the company’s ability to monetize technology ahead of own product commercialization.
Collaboration-driven Business ModelA partnership/licensing model delivers non-dilutive, milestone-linked cash inflows and external validation of the base-editing platform. These recurring collaboration structures can sustainably fund R&D and de-risk parts of the pipeline while leveraging partner commercialization capabilities.
Bears Say
High Cash BurnSubstantial negative operating and free cash flow create persistent funding needs. Over the medium term the company will depend on financing, partnerships, or milestone receipts; repeated raises can dilute shareholders and compress strategic optionality if capital markets tighten.
Persistent UnprofitabilityDeep negative margins and negative returns indicate current operations do not generate sustainable economic profits. Until clinical success or product sales materialize, continued losses can erode equity and constrain reinvestment capacity, raising execution risk over months.
Pipeline/clinical-stage RiskRelying on a pre-commercial pipeline concentrates company value in clinical and regulatory milestones that are binary and time-consuming. Delays, trial failures, or partner reprioritization could materially reduce future revenue and jeopardize projected commercialization pathways.
Beam Therapeutics News
BEAM FAQ
What was Beam Therapeutics’s price range in the past 12 months?
Beam Therapeutics lowest stock price was $15.60 and its highest was $38.26 in the past 12 months.
What is Beam Therapeutics’s market cap?
Beam Therapeutics’s market cap is $2.58B.
When is Beam Therapeutics’s upcoming earnings report date?
Beam Therapeutics’s upcoming earnings report date is Aug 11, 2026 which is in 15 days.
How were Beam Therapeutics’s earnings last quarter?
Beam Therapeutics released its earnings results on May 07, 2026. The company reported -$0.91 earnings per share for the quarter, beating the consensus estimate of -$1.028 by $0.118.
Is Beam Therapeutics overvalued?
According to Wall Street analysts Beam Therapeutics’s price is currently Undervalued.
Does Beam Therapeutics pay dividends?
Beam Therapeutics pays a Quarterly dividend of $0.225 which represents an annual dividend yield of N/A. See more information on Beam Therapeutics dividends here
What is Beam Therapeutics’s EPS estimate?
Beam Therapeutics’s EPS estimate is -1.11.
How many shares outstanding does Beam Therapeutics have?
Beam Therapeutics has 102,879,210 shares outstanding.
What happened to Beam Therapeutics’s price movement after its last earnings report?
Beam Therapeutics reported an EPS of -$0.91 in its last earnings report, beating expectations of -$1.028. Following the earnings report the stock price went down -2.69%.
Which hedge fund is a major shareholder of Beam Therapeutics?
Currently, no hedge funds are holding shares in BEAM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beam Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.91 (110.79% Upside)
$52.91 (110.79% Upside)
Blogger Sentiment
Bullish
BEAM Sentiment 83%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $10.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.80%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.95%
Trailing 12-Months
Company Description
Beam Therapeutics
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
BEAM Stock 12 Month Forecast
Average Price Target
$52.91
▲(110.79% Upside)
Technical Analysis
Denali Therapeutics
―
Immunovant
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Immunocore Holdings
―
Ownership Overview
3.39% Insiders
21.84% Mutual Funds
0.23% Other Institutional Investors
45.34% Public Companies and Individual Investors